AgomAb Therapeutics

graphic of intestines

Biotech

Agomab's ALK5 inhibitor hits intestinal target in Crohn's trial

Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease.

James Waldron Mar 10, 2025 8:50am

piggy bank cash money pay

Agomab uses $100M series C to push Crohn's drug through phase 2

Oct 11, 2023 8:50am

Fierce Biotech's 2022 Fierce 15

Sep 12, 2022 3:00am

money private equity venture capital investment cash dollar sign investor

Pfizer jumps into bed with Agomab, leading series B extension

Jul 13, 2022 10:10am

Person and parachite after landing in snow

CRISPR cans R&D chief in SEC filing—Chutes & Ladders

Dec 22, 2021 9:30am

AgomAb

AgomAb raises $74M to develop regenerative pathway modulators

Mar 10, 2021 5:00am